Edition:
India

Knight Therapeutics Inc (GUD.TO)

GUD.TO on Toronto Stock Exchange

7.62CAD
6 Dec 2019
Change (% chg)

-- (--)
Prev Close
$7.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
259,696
52-wk High
$8.88
52-wk Low
$7.10

Latest Key Developments (Source: Significant Developments)

Knight Therapeutics Inc Says Co, Medison Biotech (1995) Ltd Have Agreed To Separate Their Businesses
Friday, 22 Nov 2019 

Nov 21 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS INC - CO, MEDISON BIOTECH (1995) LTD HAVE AGREED TO SEPARATE THEIR BUSINESSES.KNIGHT THERAPEUTICS - KNIGHT WILL SELL TO MEDISON GROUP ALL OF KNIGHT'S SHARES IN MEDISON, REFLECTING APPROXIMATELY 28.3% OF SHARE CAPITAL OF MEDISON.KNIGHT THERAPEUTICS INC - KNIGHT WILL SELL TO MEDISON GROUP ALL OF KNIGHT'S SHARES IN MEDISON IN CONSIDERATION FOR C$77 MILLION PAYABLE IN CASH.KNIGHT THERAPEUTICS INC - CO, MEDISON AGREED TO RELEASE EACH OTHER FROM ALL CLAIMS AND WITHDRAW ALL LEGAL PROCEEDINGS INITIATED BY BOTH PARTIES.KNIGHT THERAPEUTICS INC - MEDISON AGREED TO A FOUR-YEAR STANDSTILL COMMITMENT AND WILL DIVEST ITS POSITION IN KNIGHT DURING THE FOUR-YEAR PERIOD.KNIGHT THERAPEUTICS INC - MEDISON, TOGETHER WITH ITS AFFILIATES OWN ABOUT 10.4 MILLION SHARES OR 7.5% OF KNIGHT.  Full Article

Knight Therapeutics Inc- QTRLY Revenue C$4 Million Versus C$ 3.2 Million
Wednesday, 13 Nov 2019 

Knight Therapeutics Inc ::KNIGHT THERAPEUTICS REPORTS THIRD QUARTER 2019 RESULTS.QTRLY LOSS PER SHARE C$0.021.QTRLY REVENUE C$4 MILLION VERSUS C$ 3.2 MILLION.Q3 EARNINGS PER SHARE VIEW C$0.03, REVENUE VIEW C$3.4 MILLION -- REFINITIV IBES DATA.  Full Article

Brazil's Biotoscana Appoints Claudio Coracini As Interim CEO After Agreement To Sell Control To Knight Therapeutics- Filing
Monday, 28 Oct 2019 

Oct 28 (Reuters) - Biotoscana Investments SA ::BRAZIL'S BIOTOSCANA APPOINTS CLAUDIO CORACINI AS INTERIM CEO AFTER AGREEMENT TO SELL CONTROL TO KNIGHT THERAPEUTICS- FILING.  Full Article

Knight Therapeutics To Acquire Grupo Biotoscana
Monday, 21 Oct 2019 

Oct 21 (Reuters) - Knight Therapeutics Inc ::KNIGHT THERAPEUTICS TO ACQUIRE GRUPO BIOTOSCANA, ESTABLISHING A LATIN AMERICAN GROWTH PLATFORM.KNIGHT THERAPEUTICS INC - DEAL FOR BRL 10.96 PER SHARE.KNIGHT THERAPEUTICS INC - WILL PAY APPROXIMATELY BRL 596 MILLION OR C$189 MILLION IN CASH CONSIDERATION FOR 51.21% CONTROLLING INTEREST IN GBT..KNIGHT THERAPEUTICS - FOLLOWING COMPLETION OF TRANSACTION, KNIGHT WILL LAUNCH A MANDATORY TENDER OFFER TO ACQUIRE REMAINING 48.79% INTEREST IN GBT.KNIGHT THERAPEUTICS INC - EXPECTED CASH CONSIDERATION IS OF APPROXIMATELY BRL 568 MILLION OR C$180 MILLION FOR REMAINING 48.79% INTEREST IN GBT.KNIGHT THERAPEUTICS - WILL ACQUIRE INTEREST IN BIOTOSCANA INVESTMENTS FROM GROUP THAT INCLUDES ADVENT INTERNATIONAL & ESSEX WOODLANDS, AMONG OTHERS.KNIGHT THERAPEUTICS INC - PRIVATE TRANSACTION WILL BE FULLY FUNDED FROM CASH ON KNIGHT'S BALANCE SHEET.KNIGHT THERAPEUTICS INC - WILL BECOME CONTROLLING SHAREHOLDER AND WILL APPOINT ITS REPRESENTATIVES TO BOARD OF GBT.KNIGHT THERAPEUTICS - FOLLOWING COMPLETION OF ACQUISITION OF 100% OF GBT, CO EXPECTS TO PAY AGGREGATE EQUITY PURCHASE PRICE OF BRL 1,164 MILLION/C$369 MILLION.KNIGHT THERAPEUTICS - FOLLOWING COMPLETION OF ACQUISITION OF 100% OF GBT, KNIGHT EXPECTS TO PAY ENTERPRISE VALUE OF BRL 1,318 MILLION OR C$418 MILLION.  Full Article

Medimetriks Pharmaceuticals Says Company Is Now Free Of Third Party Debt
Wednesday, 19 Jun 2019 

June 18 (Reuters) - Knight Therapeutics Inc ::MEDIMETRIKS PHARMACEUTICALS FOCUSES ON ADVANCING MM36 (DIFAMILAST) THROUGH PHASE 3 TRIALS; EXTINGUISHES DEBT OWED TO KNIGHT THERAPEUTICS.MEDIMETRIKS PHARMA - IS IN DISCUSSIONS FOR FINANCING OPTIONS TO ADVANCE MM36 (DIFAMILAST) THROUGH PHASE 3 PIVOTAL TRIALS AND POTENTIAL FDA APPROVAL.MEDIMETRIKS PHARMACEUTICALS - COMPANY EXTINGUISHED FINAL DEBT OWED KNIGHT THERAPEUTICS AND IS NOW FREE OF THIRD PARTY DEBT.  Full Article

TherapeuticsMD And Theramex Enter Into Exclusive License And Supply Agreement To Commercialize Bijuva And Imvexxy
Friday, 7 Jun 2019 

June 7 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD AND THERAMEX ENTER INTO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT TO COMMERCIALIZE BIJUVA™ AND IMVEXXY® OUTSIDE THE UNITED STATES.THERAPEUTICSMD INC - AGREEMENT LEVERAGES THERAMEX'S EXTENSIVE WOMEN'S HEALTH CAPABILITIES AND INFRASTRUCTURE TO BENEFIT OF MENOPAUSAL WOMEN OUTSIDE OF U.S..THERAPEUTICSMD INC - THERAPEUTICSMD TO RECEIVE EUR 14 MILLION AS AN UPFRONT FEE.THERAPEUTICSMD INC - IS ELIGIBLE TO RECEIVE UP TO EUR 29.5 MILLION IN REGULATORY AND SALES MILESTONE PAYMENTS, AS WELL AS A ROYALTY ON NET SALES.THERAPEUTICSMD INC - THERAPEUTICSMD IS ALSO ENTITLED TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF BIJUVA AND IMVEXXY IN LICENSED TERRITORIES.THERAPEUTICSMD - CO ENTITLED TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF BIJUVA AND IMVEXXY IN LICENSED TERRITORIES.THERAPEUTICSMD-THERAMEX WILL BE RESPONSIBLE FOR CONDUCTING REGULATORY AND COMMERCIAL ACTIVITIES RELATED TO BIJUVA AND IMVEXXY IN LICENSED TERRITORIES.THERAPEUTICSMD INC - THERAMEX WILL HAVE EXCLUSIVE COMMERCIALIZATION RIGHTS FOR BIJUVA AND IMVEXXY OUTSIDE U.S., EXCLUDING CANADA AND ISRAEL.  Full Article

Knight Therapeutics Reports Q1 Basic EPS Of $0.04
Thursday, 9 May 2019 

May 9 (Reuters) - Knight Therapeutics Inc ::KNIGHT REPORTS FIRST QUARTER 2019 RESULTS.KNIGHT THERAPEUTICS INC QUARTERLY BASIC EARNINGS PER SHARE $0.04.KNIGHT THERAPEUTICS INC QUARTERLY REVENUES $2.96 MILLION VERSUS $3.15 MILLION.  Full Article

Medison Biotech - Co, Together With Affiliates Owns More Than 10.4 Million Shares Or 7.3% Of Knight Therapeutics
Friday, 3 May 2019 

May 3 (Reuters) - Knight Therapeutics Inc ::MEDISON BIOTECH - CO, TOGETHER WITH AFFILIATES OWNS MORE THAN 10.4 MILLION SHARES OR 7.3% OF KNIGHT THERAPEUTICS.MEDISON BIOTECH - MEDISON PLEDGES TO PURSUE ITS DIAMOND STRATEGY IN CANADA INDEPENDENTLY.MEDISON BIOTECH - "REMAINS COMMITTED TO ONGOING ENGAGEMENT WITH SHAREHOLDERS TO BRING NECESSARY CHANGE TO KNIGHT, INCLUDING AT VERY NEXT OPPORTUNITY".  Full Article

Medison Biotech Ltd Says Released Correspondence It Got From Knight's Lawyers And Accountants
Friday, 15 Mar 2019 

March 15 (Reuters) - Knight Therapeutics Inc ::MEDISON BIOTECH LTD - RELEASED CORRESPONDENCE IT GOT FROM KNIGHT'S LAWYERS AND ACCOUNTANTS.  Full Article

Medison Biotech Sends Open Letter To Knight Therapeutics Board
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Medison Biotech Ltd::SENT AN OPEN LETTER TO KNIGHT THERAPEUTICS'S BOARD.SAYS BOARD SHOULD INSIST JONATHAN GOODMAN RELINQUISH HIS ROLE AT KNIGHT THERAPEUTICS OR HIS FINANCIAL STAKE IN COMPETING FAMILY BUSINESS.SAYS TOGETHER WITH ITS AFFILIATES OWNS MORE THAN 10.4 MILLION SHARES, OR 7.3 PERCENT OF KNIGHT THERAPEUTICS.  Full Article

Deals of the day-Mergers and acquisitions

Oct 29 The following bids, mergers, acquisitions and disposals were reported by 13:30 GMT on Tuesday: